Skip to main content

Table 3 Incidence of hematological and nonhematological toxicities

From: Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer

Type of toxicity

Grade 1 to 2

Grade 3 to 4

 

Ce-SOX

SOX

P

Ce-SOX

SOX

P

Hematological

22 (73.3)

17 (65.4)

0.52

10 (33.3)

11 (42.3)

0.58

Thrombocytopenia

6 (20.0)

5 (19.2)

0.94

2 (6.6)

2 (7.7)

1.0

Neutropenia

16 (53.3)

12 (46.2)

0.59

8 (26.7)

9 (34.6)

0.57

Nonhematological

16 (53.3)

21 (80.8)

0.03

3 (10.0)

5 (19.2)

0.53

Nausea and vomiting

1 (3.3)

8 (30.8)

0.008

1 (3.3)

2 (7.7)

0.59

Diarrhea

0 (0)

1 (3.8)

0.46

0 (0)

1 (3.8)

0.46

Mucositis

1 (3.3)

2 (7.7)

0.59

0 (0)

0 (0)

-

Hand-foot syndrome

2 (6.7)

1 (3.8)

0.55

1 (3.3)

1 (3.8)

1.0

Peripheral neuropathy

8 (26.7)

1 (3.8)

0.029

1 (3.3)

0 (0)

0.68

Hepatic dysfunction

3 (10.0)

2 (7.7)

0.67

0 (0)

1 (3.8)

0.72

Renal dysfunction

1 (3.3)

6 (23.1)

0.04

0 (0)

0 (0)

-